Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Colorcon
Mallinckrodt
Moodys
Express Scripts

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR AMIODARONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Amiodarone Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000464 ↗ Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1987-04-01 To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals who had survived one episode of out-of-hospital cardiac arrest.
NCT00000464 ↗ Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed University of Washington Phase 3 1987-04-01 To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals who had survived one episode of out-of-hospital cardiac arrest.
NCT00000531 ↗ Antiarrhythmics Versus Implantable Defibrillators (AVID) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1992-09-01 To evaluate if use of an implantable cardiac defibrillator (ICD) results in reduction in total mortality, when compared with conventional pharmacological therapy, in patients resuscitated from sudden cardiac death who are otherwise at very high risk of mortality from arrhythmic causes.
NCT00000556 ↗ Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1995-03-01 To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.
NCT00000609 ↗ Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1997-05-01 To compare conventional treatment of congestive heart failure (CHF) with two experimental interventions: amiodarone and an implantable cardioverter-defibrillator (ICD).
NCT00006330 ↗ Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn Completed National Center for Research Resources (NCRR) N/A 1969-12-31 Hawthorn (Crataegus oxyacantha) is a natural product that is popular in European and American herbal medicine practice. Some of its cardiac uses include the treatment of high and low blood pressure, rapid heart beat, chest pain, and blocked arteries. In many cases, it is used as an adjuvant agent with other cardiac drugs such as digoxin, amiodarone, and warfarin. To date, little information is known about the effect of hawthorn when taken with other drugs and if toxicities occur when hawthorn is used with other drugs. The purpose of this study is to examine the interaction between digoxin and hawthorn in eight healthy subjects. Subjects will be recruited by advertisement. The design of the study will include a 10-day and a three-week treatment phase of digoxin 0.125 mg - 0.25 mg/day and hawthorn (Crataegus special extract WS1442, Schwabe Co.) 450 mg twice daily or placebo, with a randomized crossover. There will be a three-week washout period in between treatment phases. On day 10 (phase I) and day 21 (phase II), subjects will have 12 blood samples drawn for pharmacokinetic analysis. The plasma samples will be measured for digoxin concentration. Additionally, the subjects will be assessed for any clinical toxicities or adverse events. The significance of this study is to provide the clinician with information regarding the safe use of digoxin in combination with the herbal supplement, hawthorn.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amiodarone Hydrochloride

Condition Name

Condition Name for Amiodarone Hydrochloride
Intervention Trials
Atrial Fibrillation 61
Ventricular Tachycardia 8
Heart Failure 7
Heart Diseases 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amiodarone Hydrochloride
Intervention Trials
Atrial Fibrillation 79
Tachycardia 17
Tachycardia, Ventricular 16
Heart Diseases 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amiodarone Hydrochloride

Trials by Country

Trials by Country for Amiodarone Hydrochloride
Location Trials
United States 224
Italy 68
Canada 42
France 15
Brazil 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Amiodarone Hydrochloride
Location Trials
Pennsylvania 14
New York 13
California 11
Texas 11
Virginia 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amiodarone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Amiodarone Hydrochloride
Clinical Trial Phase Trials
Phase 4 46
Phase 3 36
Phase 2/Phase 3 8
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amiodarone Hydrochloride
Clinical Trial Phase Trials
Completed 63
Unknown status 23
Recruiting 16
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amiodarone Hydrochloride

Sponsor Name

Sponsor Name for Amiodarone Hydrochloride
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 7
Sanofi 7
Abbott Medical Devices 6
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amiodarone Hydrochloride
Sponsor Trials
Other 215
Industry 54
NIH 10
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
Mallinckrodt
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.